Skip to content

Serotonin: all studies

Page 242 of 400: studies 2,411 to 2,420 of 3,999, newest first. Back to the serotonin overview

Research

Philosophical Perspectives on Psychedelic Psychiatry

September 13, 2024 Chris Letheby, Philip Gerrans 6 citations

Abstract A recent wave of research in psychiatry and neuroscience has re-examined the properties of ‘classic’ psychedelic substances—also known as serotonergic hallucinogens—such as psilocybin, lysergic acid diethylamide (LSD), and N,N-dimethyltryptamine (DMT). Evidence to date suggests that psychedelics can be given safely in controlled conditions, at moderate to high doses, and may have...

DOI: 10.1093/oso/9780192898371.001.0001 (opens in new tab) Psychoanalysis Psychotherapist Cognitive science

B - 61 Psilocybin as a First-Line Treatment of ADHD in Adult Populations

Archives of Clinical Neuropsychology September 12, 2024 James Perry, Cara C. Young, Julie Williams 1 citation

Abstract Objectives The first line for symptom management of attention deficit hyperactivity disorder (ADHD) is a class of medications that act on dopamine and noradrenaline receptors, which leads to symptom reduction at the cost of significant side effects. These side effects have led to community searching for alternative methods that manage ADHD symptoms in adults that lead to less side...

Co-administration of midazolam and psilocybin: differential effects on subjective quality versus memory of the psychedelic experience.

Translational Psychiatry September 12, 2024 Christopher R. Nicholas, Matthew I Banks, Richard C Lennertz et al. 10 citations

Aspects of the acute experience induced by the serotonergic psychedelic psilocybin predict symptomatic relief in multiple psychiatric disorders and improved well-being in healthy participants, but whether these therapeutic effects are immediate or are based on memories of the experience is unclear. To examine this, we co-administered psilocybin (25 mg) with the amnestic benzodiazepine midazolam...

Psilocybin alters brain activity related to sensory and cognitive processing in a time-dependent manner

medRxiv September 11, 2024 Marek Nikolič, Pedro A. M. Mediano, Tom Froese et al. 6 citations preprint

Abstract Psilocybin is a classic psychedelic and a novel treatment for mood disorders. Psilocybin induces dose-dependent transient (4-6 hours) usually pleasant changes in perception, cognition, and emotion by non-selectively agonizing the 5-HT 2A receptors and negatively regulating serotonin reuptake, and long-term positive antidepressant effect on mood and well-being. Long-term effects are...

DOI: 10.1101/2024.09.09.24313316 (opens in new tab) Psilocybin Cognition Sensory system Sensory processing +2

Neurobiological research on N,N-dimethyltryptamine (DMT) and its potentiation by monoamine oxidase (MAO) inhibition: from ayahuasca to synthetic combinations of DMT and MAO inhibitors.

Cellular and Molecular Life Sciences September 10, 2024 Klemens Egger, Helena Aicher, Paul Cumming et al. 30 citations

The potent hallucinogen N,N-dimethyltryptamine (DMT) has garnered significant interest in recent years due to its profound effects on consciousness and its therapeutic psychopotential. DMT is an integral (but not exclusive) psychoactive alkaloid in the Amazonian plant-based brew ayahuasca, in which admixture of several β-carboline monoamine oxidase A (MAO-A) inhibitors potentiate the activity...

Epigenetic mechanisms of rapid-acting antidepressants

Translational Psychiatry September 4, 2024 Antonio Inserra, Antonella Campanale, Tamim Rezai et al. 24 citations

BACKGROUND: Rapid-acting antidepressants (RAADs), including dissociative anesthetics, psychedelics, and empathogens, elicit rapid and sustained therapeutic improvements in psychiatric disorders by purportedly modulating neuroplasticity, neurotransmission, and immunity. These outcomes may be mediated by, or result in, an acute and/or sustained entrainment of epigenetic processes, which remodel...

DOI: 10.1038/s41398-024-03055-y (opens in new tab) Full text (opens in new tab) Epigenetics Psychopharmacology Schizophrenia object-oriented programming Bioinformatics

G33 Psychedelic drugs for the treatment of chronic pain: is ketamine included?

Ask the expert – Psychedelic substances September 1, 2024 A. E. Ayad

One of the main causes of misery and incapacity is chronic pain, which is frequently linked to psychological issues. Psychedelic substances are drugs that can exert a psychological effect on patients. Psychedelic drugs like lysergic acid diethylamide (LSD) and psilocybin, exert their action mainly via activation of the serotonin-2A (5-HT2A).1 In a trial to understand the actual mode of action...

Use of Psychedelic Drugs in Psychiatry

September 1, 2024 Franklin King Iv

Differentiate between classic psychedelics and their mechanisms of action. Describe how psychedelics influence brain networks, particularly the default mode network, and explain the potential therapeutic implications of these effects on conditions like depression. Outline the key components of psychedelic-assisted therapy, including preparation, support during the psychedelic session, and...

Profiling the combination of bupropion and dextromethorphan as a treatment option for major depressive disorder.

Expert Review of Neurotherapeutics September 1, 2024 Joseph Blanco, Pamela Quimbaya, Manuel Mena et al.

Major Depressive Disorder (MDD) is a common mental health disorder marked by sadness, hopelessness, and anhedonia. Various therapies exist, but their effectiveness is limited. Dextromethorphan hydrobromide combined with bupropion hydrochloride (Auvelity®) is a recently approved alternative for treating this condition in adults. This review summarizes the neurobiology of major depression and...

DOI: 10.1080/14737175.2024.2374024 (opens in new tab) Full text (opens in new tab) Dextromethorphan Auvelity® Bupropion Neuropharmacology

Rosalind Franklin Society Proudly Announces the 2023 Award Recipient for Psychedelic Medicine

Psychedelic Medicine September 1, 2024 Albert Garcia‐romeu

Rationale: N-methyl-D-aspartate receptor-mediated dissociatives and serotonergic hallucinogens are being increasingly used in therapeutic interventions that involve nonordinary states of consciousness and may represent a unique mental health paradigm wherein pharmacologically induced experiences are conducive to psychological well-being. Objective: The aim of this study was to further...